Objective: Genomic studies of ovarian cancer (OC) 
Introduction 55
Ovarian cancer (OC) is the fifth leading cause of cancer-related deaths among 56 and mesenchymal [13] . While these categories are well established in primary and 78 recurrent HGSOC tumors, the ability to correlate genomic and molecular features with 79 useful laboratory model systems is critical for the future development of new therapies, 80 prevention strategies, and imaging studies [14] . 81
Recent publications have characterized an expanded panel of OC cell lines at 82 the genomic level, in 2-dimesional-cell culture (on plastic), and in regards to their in vitro 83 response to chemotherapeutic drugs [15] [16] [17] . These reports further suggested that OC 84 cell lines commonly used in the past (e.g. SKOV3, A2780) do not represent a good 85 approximation of the HGSOC genotype and that a panel of recently described cell lines 86 more closely resemble human serous tumor. However, several of the newly proposed 87 models for HGSOC have never been characterized for the ability to form tumors in 88 immune deficient mice, which is critical to study mechanisms of disease or therapeutic 89 interventions in vivo. The goal of this study was to determine the tumorigenic ability of 90 newly described HGSOC cell lines and the histologic characteristics of the xenografts 91 derived from these cells. 92
93

Materials and Methods 94
Cell culture 95
All reagents were obtained from Life Technologies (Carlsbad, CA) unless otherwise 96 Tissues were fixed in 4% paraformaldehyde before dehydration in ethanol and xylene 142 prior to paraffin embedding. Immunohistochemistry and hematoxylin and eosin (H&E) 143 staining was performed as previously described [18] . Briefly, tissues were sectioned and 144 rehydrated in a gradient of ethanol prior to antigen retrieval and peroxidase block. and SNU119 after 90 days of observation, and these three OC lines were considered to 169 be non-tumorigenic. The data in Table 1 The location of metastasis in the peritoneal space after i.p. injection was also 181 examined. Disseminated tumorigenic cells were observed on peritoneal surfaces, the 182 gastrointestinal tract, particularly the small bowel, and the omentum (Table 2) based on their rapid growth in vivo, may be useful to reduce the length and cost of 231 xenograft studies. However, because OVCAR5 and OVCAR8 i.p. tumor growth is widely 232 disseminated, it may be a challenge to quantitate initial tumor burden as well as 233 changes in tumor growth in response to therapy. Take rates were remarkably 234 consistent between the cell models that produced tumors, suggesting that if grafted, 235 these models are reliable. OVSAHO and OVKATE were both very slow growing in vivo 236 and in vitro, and it seems reasonable to suggest that they would both form i.p. disease 237 with more cells or more time. OVCAR3 and OVCAR8 formed the largest tumor masses 238 and these lines may be extremely useful in conjunction with in vivo optical imaging 239 technologies or drug accumulation and biodistribution studies with nanocarriers. For the 240 cells that formed tumors, there was a remarkable divergence in organs colonized, 241 although the organs were similar to those seen in human disease. All cell models 242 colonized the GI tract and liver and the second most common site of tumor formation 243 was the reproductive tract, suggesting that these models may be appropriate to study 244 interactions between tumor cells and the microenvironment, in general as well as at 245 specific sites in vivo. 246
In this initial analysis, there was no apparent correlation between the mutational 247 spectrum of the cell lines and in vivo growth characteristics. All of the models in this 248 study have p53 mutations except for OVCAR5, which is p53 null. Otherwise the 249 mutational spectrum for these lines is dramatically different, and each could therefore 250 be a model for a specific target, such as BRCA1 (for COV362 as a s.c. model), c-myc 251 (COV362 as a s.c. model), cyclin E (OVCAR3), mutation in ERBB2 (OVCAR8) or loss of 252
Rb (OVSAHO)[17]. Interestingly, previous reports based on in vitro 253
immunocytochemistry studies performed on the cell lines found CAOV3 and OVCAR4 254 to be negative for p53 and WT1. In contrast, our in vivo study found that these markers 255 are expressed in tumors from both of these cell lines [16] . OVCAR5 and OVCAR3 were 256 identical at the cellular and tumor level for p53 and WT1 expression. OVCAR8 257 expressed WT1 mostly in the nucleolar compartment, which has previously been 258 described in mucinous tumors [22] . Only three of the models tested here in vivo 259 (COV362, OVCAR3, and CAOV3) were also screened for chemotherapy sensitivity in 260 vitro [16] . All three models appeared to be relatively sensitive to chemotherapy and also 261 had almost exactly the same doubling time in vitro, between 51-56 hours [16] , yet in 262 vivo OVCAR3 was much more aggressive ( Figure 1 ). In summary, the development of 263 more reliable and authenticated models of HGSOC has been dramatically improved by 264 recent reports characterizing their genomes, behavior in vitro, and sensitivity to drugs. 265
This report adds to the growing information and helps to define which HGSOC models 266 reliably generate tumors and/or ascites, essential information for their use in drug 267 discovery, imaging, and prevention studies. 
